A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Titel:
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Auteur:
Stover, Elizabeth H. Xiong, Niya Myers, Andrea P. Tayob, Nabihah Engvold, Victoria Polak, Madeline Broaddus, Russell R. Makker, Vicky Drapkin, Ronny Liu, Joyce F. Horowitz, Neil S. Meric-Bernstam, Funda Aghajanian, Carol Coleman, Robert L. Mills, Gordon B. Cantley, Lewis C. Matulonis, Ursula A. Westin, Shannon N. Konstantinopoulos, Panagiotis A.